cyrilzakka/clinical-trials huggingface dataset:
The Effectiveness of Massage in Treating Constipation

The purpose of this study is to compare the effectiveness of massage based on the tensegrity rule and classical abdominal massage in persons with constipation.

Constipation can be defined as "an embarrassing ailment of the 21st century". It affects about 20-25% of the population, women as well as men, but occurs more frequently in women (female:male ratio of 2.2:1). Persons of different age suffer from it. Constipation is a bothersome ailment which negatively affects the general physical and mental state, lowers physical and mental fitness, significantly hinders professional work, and decreases life comfort As the factors which contribute to the occurrence of constipation are very diverse and complex, the treatment is a long-term and slow process. There are numerous conservative treatment methods for constipation, such as physical treatments, reflexotherapy, biofeedback, pharmacotherapy, and modification of lifestyle. There is also a possibility of applying classical massage in persons with constipation. However, observations of the authors suggest it is not a therapy commonly applied.

Eligibility Criteria:
Inclusion Criteria:

1. age from 18 to 70 years old
2. after therapy with Vermoks 2\*1/ 3 regardless of body weight
3. negative Elis test for lambliasis
4. proper laboratory tests results: bilirubin, FA, GGTP, AspAT, AlAT
5. ultrasound scan of the abdominal cavity
6. positive interview based on questionnaire

Exclusion Criteria:

1. present cancer or prior cancer treatment, if there is no clear agreement of the involved oncologist
2. renal insufficiency \> II NYHA
3. cardiovascular problems
4. respiratory insufficiency \> II degree GOLD
5. unstable coronary disease
6. hypertensive crisis
7. liver insufficiency
8. prior liver transplant
9. prior or active hepatitis
10. jaundice
11. prior surgical treatments except: appendectomy \>5 years before, cholecystectomy 5 years before
12. unequalized endocrinopathies
13. metabolic storage diseases
14. diabetes
15. nephrolithiasis
16. cholelithiasis
17. pancreatitis
18. chronic diseases of the intestines
19. diseases of the muscles
20. pregnancy
21. parasite infections of the digestive system (infection with human roundworm, lambliasis)
22. age above 18 years old
23. BMI\> 33
24. improper ultrasound scan result or laboratory tests results
25. blood presence in feces
Comparative Effects of Lower Body Quadrant Neural Mobilization and Stretching in Collegiate Football Players

Neural mobilization (NM) refers to a therapeutic interventions that aim to directly or indirectly influence neural structures and adjacent tissues through manual techniques or exercise. The application of NM has been investigated in both patients and healthy individuals. In this study, participants from an amateur football team will be allocated into three groups, each undergoing pre-training warm-up protocols incorporating NM, dynamic stretching, or static stretching. Following the warm-up protocols, the effects on flexibility and athletic performance will be evaluated and compared across the groups.

Neural mobilization (NM) is an intervention that involves manual techniques or exercises designed to affect neural structures and surrounding tissues. It aims to restore normal neural mechanical and physiological responses to movement and posture by facilitating the sliding and tension of the nerves. NM techniques can be divided into two groups: gliding, which involves different joint movements, and tension, which extends the nerves in more than one joint. Although NM has been linked to various neurophysiological benefits, the precise mechanisms underlying its clinical efficacy remain uncertain.

The peripheral nervous system demonstrates the ability to adapt to changing mechanical forces encountered during daily activities and sports through nerve gliding and sliding mechanisms. Impaired gliding may result in increased neural stress and ischemic damage, affecting neural function. NM has been shown to improve lower extremity flexibility, which is crucial for enhancing functionality and minimizing injury risk in athletes. Neurodynamic techniques are frequently used to increase hamstring flexibility and reduce neural mechanosensitivity, contributing positively to athletic performance and injury prevention.

The aim of this study is to examine the comparative effects of static stretching, dynamic stretching and neural mobilization techniques used in pre-training warm-up sessions on flexibility and performance in collegiate football players.

Eligibility Criteria:
Inclusion Criteria:

* Between the ages of 18-25
* Not having had a lower or upper extremity injury in the last 3 months
* Not having had surgery in the last 6 months
* Playing amateur football regularly for at least 1 year

Exclusion Criteria:

* Orthopedic, neurological, rheumatological or cardiorespiratory health problems that would prevent them from performing the tests
Arginine Therapy for Sickle Cell Disease Pain

The aim of this study is to determine whether giving extra arginine, a simple amino acid, to patients with sickle cell disease seeking treatment for a pain crisis (vaso-occlusive painful events (VOE) will decrease pain scores, decrease the need for pain medications or decrease length of hospital stay or emergency department visit. Funding Source - FDA OOPD.

The purpose of this study is to determine the effects of IV L-arginine hydrochloride therapy in children with sickle cell disease (SCD) and vaso-occlusive pain events (VOE). Specifically, the impact on total opioid use (mg/kg) over the duration of their emergency department (ED) visit and hospital stay will be evaluated.

Eligibility Criteria:
Inclusion Criteria:

* Established diagnosis of sickle cell disease (SCD); all genotypes
* Pain requiring medical care in an acute care setting (such as the emergency department or ED, hospital ward, day hospital, clinic) not attributable to non-sickle cell causes, that is moderate-to-severe requiring parenteral opioids

Exclusion Criteria:

* Decision to discharge home from the acute care setting
* Hemoglobin less than 5 gm/dL or immediate need for red cell transfusion anticipated within next 12 hours
* Hepatic dysfunction of SGPT greater than 3 times the upper value
* Renal dysfunction of creatinine greater than 1.0
* Mental status or neurological changes
* Acute stroke or clinical concern for stroke
* Pregnancy
* Allergy to arginine
* Two (2) or more ED visits for VOE within the last 7 days prior to CURRENT ED visit
* Hospitalization within 14 days
* Previous randomization in this arginine RCT (patient consented and screen failed before receiving study drug or placebo remains eligible for future participation).
* Use of inhaled nitric oxide, sildenafil or arginine within the last month
* PICU admission from the emergency department
* Hypotension requiring treatment with clinical intervention
* Acidosis with Co2≤ 16
* Newly started on HU for \<3 months
* Not an appropriate candidate in the investigator's judgment
* Patient refusal
MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)

Invasive aspergillosis is a type of fungal infection typically identified in very sick patients (for example, patients with cancer or who have had a bone marrow or organ transplant). This study will seek to enroll patients (16 years of age or older) with invasive aspergillosis infections (involving organs or deep tissues) who are failing or could not tolerate standard antifungal therapy. Your doctor will make this determination based upon specific study criteria. Patients that fulfill all study criteria will be treated daily with both the investigational drug and another antifungal agent. The choice of the other agent is up to your doctor. This investigational drug is approved for the treatment of invasive aspergillosis by itself. The safety and efficacy of this investigational drug, in combination with other agents is not known.

The duration of treatment is 12 months.

Eligibility Criteria:
* Patients must meet a specific definition of probable or definite invasive aspergillosis and be considered to have failed or be intolerant of standard antifungal therapy.
* The patient must be at least 16 years old and if a woman of childbearing potential, must have a negative serum or urine pregnancy test sensitive to 25 IU hCG prior to enrollment.
Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease

The aim of the study is to assess impact of Fecal Microbiota Transfer (FMT) on clinical symptoms of Parkinson's disease. Assesment of tremor, slowness of movements and balance problems before and after FMT will be performed. The effect of FMT on frequency of constipations, which are common among Parkinson disease patients and have negative impact on quality of life and drug absorption will also be assessed. Detailed assessment of absorption of levodopa, which is the golden standard of treatment of Parkinson disease, is planned. It is planned to recruit 40 patients with diagnosis of Parkinson disease and indications for colonoscopy (constipations, age \>50 years). Patients will be randomly assigned to the group receiving treatment with FMT or identically looking placebo. It will be administered to intestine during colonoscopy. Patients will be assessed by neurologist few times after the procedure. Psychological assessment and examination of gait and balance by physiotherapist is also planned. The last assessment will be performed after 12 months to see if the clinical effect can be observed for such a long time. The composition of the intestinal microbiota will be carefully assessed before and after the procedure in order to identify pathogens that may affect the course of the disease.


Eligibility Criteria:
Inclusion Criteria:

* Idiopathic PD
* Consent to undergo colonoscopy

Exclusion Criteria:

* perforation or obstruction of gastroenteric tract,
* radiotherapy of abdomen or pelvis region
* severe heart, liver or kidney failure
* coagulation disorders
* immunity disorders
* current viral, bacterial or fungal infection
* abdominal aortic aneurysm qualifying for surgery, pregnancy and lactation treatment with Duodopa, deep brain stimulation or apomorphine
* colonoscopy confirmed colon polyps, except for lesions \<5 mm qualified for the NBI International Colorectal Endoscopic I group or other potentially neoplastic lesions after evaluation in white light and narrow beam imaging (NBI)
* severe food allergy with a history of anaphylaxis after consumption of the product.
* microbiological stool evaluation with detection of: methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae carbapenemase (KPC), metallo-β-lactamase (MBL), extended-spectrum beta-lactamase (ESBL), vancomycin-resistant Enterococci (VRE), Salmonella, Shigella, Yersinia. If any other atypical pathogen are to be detected in general stool culture, it will be assessed on an individual basis.
Non-interventional Study in Pediatric Patients Treated With NOVOCART Inject in the Knee

The study is a prospective, multicenter, single-arm non-interventional study to evaluate the efficacy, safety and health economics of NOVOCART® Inject in the treatment of cartilage defects of the knee in pediatric patients with radiologically proven closed epiphyseal growth plates.

In this non-interventional study NOVOCART® Inject, which is marketed in Germany under a license according to Section 4b of the AMG, will be used in routine clinical practice according to the current authorized Summary of Product Characteristics (SmPC). As stated in this SmPC, NOVOCART® Inject may only be used by physicians who are trained on the product. The treatment with NOVOCART® Inject requires two surgeries. During the first surgery cartilage tissue will be harvested arthroscopically and sent to TETEC AG for NOVOCART® Inject manufacturing, then NOVOCART® Inject will be transplanted during a second surgery about 3 to 4 weeks later.

All patients will be followed up for 5 years post NOVOCART® Inject implantation and data will be collected preoperatively and at 3, 6, 12, 18, 24, 36, 48 and 60 months as outlined at the end of this synopsis.

NOVOCART® Inject post treatment rehabilitation should follow the recommendations given in the SmPC and during product training.

The primary and secondary variables (see below) will be assessed after a follow-up of 24 month post NOVOCART® Inject implantation (primary analysis).

Long-term data will be assessed after an additional 3 years follow-up (follow-up analysis).

The collected data will be documented using dedicated case report forms (CRFs) which are created by TETEC AG.

Eligibility Criteria:
Inclusion Criteria:

* Pediatric patients (\< 18 years of age at implantation)
* Closure of the epiphysis adjacent to the biopsy harvest site or the defect to be treated confirmed by an adequate imaging modality
* Localized full-thickness cartilage defect (ICRS grade III or IV) of the knee
* Medicinal indication for NOVOCART® Inject treatment

Exclusion Criteria:

see NOVOCART Inject SmPC
Continuous Chest Compressions vs AHA Standard CPR of 30:2

The primary aim of the trial is to compare survival to hospital discharge after continuous chest compressions (CCC) versus standard American Heart Association (AHA) recommended cardiopulmonary resuscitation (CPR) with interrupted chest compressions (ICC) in patients with out-of-hospital cardiac arrest (OOHCA). The primary null hypothesis will be that the rate of survival to hospital discharge is not affected by use of continuous compressions with passive or positive pressure ventilation (intervention group) versus CPR with compressions interrupted for ventilation at a ratio of 30:2 (control group).

The primary aim of the trial is to compare survival to hospital discharge after continuous chest compressions (CCC) versus standard American Heart Association (AHA) recommended cardiopulmonary resuscitation (CPR) with interrupted chest compressions (ICC) in patients with out-of-hospital cardiac arrest (OOHCA). For this study, CCC consists of a series of three cycles of continuous chest compressions without pauses for ventilation followed by rhythm analysis or until restoration of spontaneous circulation (ROSC), whichever occurs first. ICC consists of series of three cycles of standard CPR each cycle comprised of chest compressions with interposed ventilations at a compression:ventilation ratio of 30:2 (per AHA guidelines) followed by rhythm analysis or until ROSC, whichever occurs first. In either patient group, the duration of manual CPR before the first rhythm analysis will be 30 seconds or 120 seconds. This treatment period will be followed by two cycles of compressions then rhythm analysis (i.e. each of approximately 2 minutes duration) in either group. Other aims of the trial are to compare survival to discharge among patients grouped by first-recorded rhythm or other a priori subgroups, as well as to compare neurological status at discharge, mechanistic outcomes or adverse events between control and intervention groups.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 years or more (or local age of consent);
* Initial fire/Emergency Medical Services (EMS) chest compressions provided by Resuscitation Outcomes Consortium (ROC) study participating agency dispatched to the scene;
* Lack of the exclusion criteria below

Exclusion Criteria:

* EMS witnessed arrest;
* Written do not attempt resuscitation (DNAR) orders;
* Obvious primary asphyxia or respiratory cause of arrest (drowning, strangulation, hanging)
* Advanced airway placed prior to ROC EMS arrival, or pre-existing tracheostomy
* Traumatic cause (blunt, penetrating, burn) of arrest;
* Known prisoners;
* Known pregnancy;
* Uncontrolled bleeding or exsanguination
* Mechanical compression device used during study-assigned compression cycles
Cohort of STEMI Patients

Ischemic heart disease is the leading cause of mortality in industrialized countries. ST elevated acute myocardial infarction is one of its most frequent and deadly manifestation. In the last 20 years, STEMI mortality has been reduced by 50% with the advent of timely reperfusion (primary percutaneous intervention) and significant progression in pharmacologic intervention.

However, death and heart failure incidence after STEMI remain elevated: up to 20% at one year.

Also, therapeutic management following international guidelines is standardized toward a "one-size fits all" therapeutic management.

In order to continue improving myocardial infarction outcomes, there is a need to better understand and individualize therapeutic targets such myocardial reperfusion injury, post reperfusion inflammation, adverse left ventricular (LV) remodeling ....

This knowledge will allow us to propose new therapeutic strategies and in the long run strive towards personalized medicine.

The aim objective of this cohort of STEMI patients is to identify new biological markers of injury and prognosis.


Eligibility Criteria:
Inclusion Criteria:

* Age\> 18 years
* Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead ECG.
* Primary PCI within 12 hours of symptoms onset.

Exclusion Criteria:

* Diagnosis of STEMI not confirmed by angiography
* Refusal to participate in the study or to sign the consent
* Inability to give information to the subject about the study
* Lack of medical social coverage
* Deprivation of civil rights
Descriptive Study of the Initial Management of Young Children With Moderate Acute BRONCHiotitis With Home Hospitalisation

The occurrence of a first episode of acute bronchiolitis in an infant or young child (3 months-2 years) always represents a medical event that generates stress for parents and in some cases for the primary care physician when it is necessary to decide on the child's orientation for treatment. Each year, during the winter season, this pathology affects 30% of infants under two years old (480,000 annual cases in France), generates approximately 30,000 hospitalizations and exposes to an overall mortality risk of 0.08%.

According to the recommendations of the HAS (2019), moderate bronchiolitis does not require systematic hospitalization and can be managed in a Home Hospitalization (HAD) context.

When the child's examination data do not find signs of severity, the SpO2 measurement is greater than 92% and the family context allows for return home, HAD management is a reasonable option and represents an alternative to the classic scheme of assessing the level of severity by the emergency department and subsequent hospitalization if necessary. HAD management is carried out within the framework of a very structured "patient pathway", codified and supervised by the pediatric teams and doctors of this department. This patient pathway concerns children with a moderate form of bronchiolitis without oxygen requirements at the time of inclusion. This must be 48 hours from the onset of the child's respiratory clinical signs.

The main objective of this study is to describe the need for oxygen therapy for a young child with moderate acute bronchiolitis syndrome during home hospitalization (HAD) care.


Eligibility Criteria:
Inclusion Criteria:

* Any infant with moderate bronchiolitis according to the HAS definition (except for the SpO2 criterion which must be greater than or equal to 92% to avoid the patient being on oxygen therapy upon admission)
* Age \> 2 months and ≤ 2 years
* Respiratory syndrome for 48 hours
* Infant with a first episode of bronchiolitis
* Referral of the general practitioner/treating pediatrician for home hospitalisation care
* Parents' agreement for the choice of home hospitalisation care
* Non-opposition or free and informed consent of both parents to the use of the child's health data

Exclusion Criteria:

* Patient not receiving health protection
* Comorbidities: congenital heart disease with shunt, chronic pulmonary pathology including bronchopulmonary dysplasia, neuromuscular pathology, immune deficiency, multiple disabilities Congenital heart disease
* Refusal of one or both parents for the proposed pathway
* Doubts about the parents' understanding of the nature of home hospitalisation care
* Severe bronchiolitis or with saturation \< 92%

  * Moderate bronchiolitis but evolving for less than 48 hours
  * Cases of psychiatric pathologies or depressive syndrome diagnosed in the parents.
Implementation of a Structured Lifestyle Program in Primary Care. Changes in Lifestyle Habits and Cardiovascular Risk.

The aim of the present study is to describe and evaluate the effect of a structured lifestyle intervention program, focusing on lifestyle habits, in a primary care setting in patients with high cardiovascular risk. Furthermore, we want to explore the patient´s experience of lifestyle change and counseling after participation in the intervention program and to investigate the cost-effectiveness of the program.

Intervention The intervention program comprises five individual visits to the same nurse, specialised in diabetes care and the metabolic syndrome every three month during one year. The nurse led a person centered dialog based on the answers from a questionnaire. At every visit, focus was primarily on lifestyle habits, using motivational interviewing to strengthen the patient's ability to modify one or more lifestyle habits. Dietary counselling was in accordance with the Swedish recommendation in nutrition. If the patient were in need of extended counseling regarding one or more lifestyle habits, he or she could be referred within the primary care unit to a specialist. During the 12-month period, all patients where offered to participate in evening group sessions at three different occasions. Topics were physical activity, fatty acids, healthy food, tobacco and alcohol, stress, sleep and methods of how to change behavior".

Eligibility Criteria:
Inclusion Criteria:

Patients diagnosed with

* hypertension
* diabetes mellitus type 2
* impaired glucose tolerance

Exclusion Criteria:

* dementia
* severe psychiatric disease
* difficulties to understand Swedish
Arterial Stiffness, Wave Reflections and Renal Failure

1. Cardiovascular risk is high in patients with renal failure.
2. Cross-sectional studies have indicated a relationship between arterial stiffness and renal function. However, there are no prospective longitudinal studies in the literature.
3. In dialysis patients, arterial stiffness as well as wave reflections, predict mortality. However, there are no data on patients with mild-to-moderate renal impairment available.
4. Therefore, we designed a study to test the hypothesis that: a) measures of arterial stiffness and wave reflections predict the progression of renal impairment in patients with mild-to-moderate renal failure; and b) measures of arterial stiffness and wave reflections predict cardiovascular events in patients with mild-to-moderate renal failure


Eligibility Criteria:
Inclusion Criteria:

* chronic renal failure patients (KDOQI III, IV) undergoing regular control visits at our nephrology department
* \> 19 years
* written informed consent

Exclusion Criteria:

* atrial fibrillation
* valvular heart disease
* severely impaired systolic function
* no informed consent
Doppler Imaging and Morbidly Adherent Placenta

The aim of this study is to assess the value of adding 3D power Doppler (as a diagnostic technique) to gray scale technique in the antenatal diagnosis of morbidly adherent placenta as well as predict the surgical outcome regarding the type of surgery and the intra operative morbidities.


Eligibility Criteria:
Inclusion Criteria:

* Age: 18 - 45.
* Pregnant 32 weeks or more.
* Placenta previa (Major and Minor).
* History of previous cesarean section.

Exclusion Criteria:

* Medical disorders such as bleeding disorders.
* Lethal fetal anomalies.
* Delivery before 34 weeks.